Baker Bros. Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-676,975
| Closed | -$63.5M | – | 120 |
|
|
2022
Q1 | $63.5M | Hold |
676,975
| – | – | 0.36% | 24 |
|
|
2021
Q4 | $57.7M | Hold |
676,975
| – | – | 0.28% | 33 |
|
|
2021
Q3 | $64.9M | Hold |
676,975
| – | – | 0.29% | 31 |
|
|
2021
Q2 | $65.9M | Hold |
676,975
| – | – | 0.29% | 31 |
|
|
2021
Q1 | $65.8M | Hold |
676,975
| – | – | 0.29% | 32 |
|
|
2020
Q4 | $64.9M | Hold |
676,975
| – | – | 0.24% | 27 |
|
|
2020
Q3 | $65.1M | Sell |
676,975
-230,011
| -25% | -$26.6M | 0.26% | 24 |
|
|
2020
Q2 | $111M | Sell |
906,986
-333,257
| -27% | -$36.8M | 0.49% | 17 |
|
|
2020
Q1 | $107M | Sell |
1,240,243
-14,000
| -1% | -$1.37M | 0.66% | 15 |
|
|
2019
Q4 | $135M | Sell |
1,254,243
-161,040
| -11% | -$16.9M | 0.72% | 16 |
|
|
2019
Q3 | $128M | Hold |
1,415,283
| – | – | 0.87% | 12 |
|
|
2019
Q2 | $119M | Buy |
1,415,283
+316,613
| +29% | +$26M | 0.81% | 14 |
|
|
2019
Q1 | $96.8M | Buy |
1,098,670
+368,315
| +50% | +$30.8M | 0.62% | 16 |
|
|
2018
Q4 | $52.2M | Sell |
730,355
-214,269
| -23% | -$20.5M | 0.43% | 22 |
|
|
2018
Q3 | $116M | Hold |
944,624
| – | – | 0.77% | 15 |
|
|
2018
Q2 | $92.8M | Hold |
944,624
| – | – | 0.7% | 16 |
|
|
2018
Q1 | $78.3M | Sell |
944,624
-60,000
| -6% | -$5.07M | 0.66% | 17 |
|
|
2017
Q4 | $77.9M | Buy |
1,004,624
+387,942
| +63% | +$26.5M | 0.68% | 15 |
|
|
2017
Q3 | $37.8M | Hold |
616,682
| – | – | 0.31% | 23 |
|
|
2017
Q2 | $28.4M | Sell |
616,682
-278,740
| -31% | -$13.5M | 0.25% | 26 |
|
|
2017
Q1 | $38.8M | Hold |
895,422
| – | – | 0.32% | 23 |
|
|
2016
Q4 | $34.7M | Hold |
895,422
| – | – | 0.34% | 24 |
|
|
2016
Q3 | $45.3M | Hold |
895,422
| – | – | 0.41% | 25 |
|
|
2016
Q2 | $40.7M | Hold |
895,422
| – | – | 0.43% | 24 |
|
|
2016
Q1 | $35.4M | Buy |
895,422
+44,683
| +5% | +$1.77M | 0.37% | 29 |
|
|
2015
Q4 | $48.1M | Buy |
850,739
+100,000
| +13% | +$5.08M | 0.4% | 28 |
|
|
2015
Q3 | $29.9M | Buy |
750,739
+208,503
| +38% | +$10.1M | 0.28% | 27 |
|
|
2015
Q2 | $25.9M | Hold |
542,236
| – | – | 0.23% | 40 |
|
|
2015
Q1 | $21.5M | Sell |
542,236
-12,354
| -2% | -$442K | 0.18% | 42 |
|
|
2014
Q4 | $12.4M | Hold |
554,590
| – | – | 0.13% | 45 |
|
|
2014
Q3 | $8.69M | Hold |
554,590
| – | – | 0.11% | 47 |
|
|
2014
Q2 | $8.23M | Buy |
554,590
+106,716
| +24% | +$1.51M | 0.1% | 48 |
|
|
2014
Q1 | $7.21M | Buy |
+447,874
| New | +$7.66M | 0.09% | 58 |
|
Other funds holding NBIX
BG
DM
EVM
Baker Bros. Advisors's NBIX Position: Q2 2022 in Review
Baker Bros. Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 676,975 shares — an estimated $63.5M sold.
Baker Bros. Advisors first reported a position in NBIX in Q1 2014 and held it in 33 quarters. The position peaked at $135M in Q4 2019. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.
- Baker Bros. Advisors reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
- Baker Bros. Advisors sold 676,975 Neurocrine Biosciences shares in Q2 2022, an estimated $63.5M.
- Baker Bros. Advisors first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 33 quarters.
- Baker Bros. Advisors's Neurocrine Biosciences position peaked at $135M in Q4 2019.
- 437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.
Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.